Payment overview · 2025
General Payments
$199.58
10 reported records · 6 companies
Healthcare provider profile · identity verified
Stephen D Kennedy, MD
Allopathic & Osteopathic Physicians|Family Medicine · PERU, IN · NPI 1700957123
Verified facts
What the public records show
CMS Open Payments records show Stephen D Kennedy, MD received $199.58 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.55 | 33.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.60 | 29.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.99 | 12.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.07 | 11.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.36 | 9.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.01 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.58 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $58.60 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 141 |
| Lisinopril | Lisinopril | 484 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 407 | 105 |
| Losartan Potassium | Losartan Potassium | 294 | 65 |
| Gabapentin | Gabapentin | 274 | 51 |
| Metformin Hcl | Metformin Hcl | 265 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 66 |
| Omeprazole | Omeprazole | 224 | 59 |
| Meloxicam | Meloxicam | 193 | 33 |
| Furosemide | Furosemide | 181 | 48 |
| Sertraline Hcl | Sertraline Hcl | 180 | 43 |
| Famotidine | Famotidine | 173 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 41 |
| Potassium Chloride | Potassium Chloride | 136 | 30 |
| Simvastatin | Simvastatin | 135 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 28 |
| Glimepiride | Glimepiride | 120 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 49 |
| Ozempic | Semaglutide | 116 | 18 |
| Eliquis | Apixaban | 115 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 22 |
| Allopurinol | Allopurinol | 103 | 27 |
| Carvedilol | Carvedilol | 102 | 25 |
| Bupropion Xl | Bupropion Hcl | 98 | 16 |
| Alendronate Sodium | Alendronate Sodium | 97 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Pregabalin | Pregabalin | 70 | 12 |
| Donepezil Hcl | Donepezil Hcl | 68 | 13 |
| Sucralfate | Sucralfate | 68 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 18 |
| Celecoxib | Celecoxib | 64 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 18 |
| Spironolactone | Spironolactone | 63 | 17 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 60 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Rybelsus | Semaglutide | 57 | suppressed |
| Azithromycin | Azithromycin | 54 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 30 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 47 | 16 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 16 |
| Naproxen | Naproxen | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Prednisone | Prednisone | 39 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Amoxicillin | Amoxicillin | 33 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 13 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Cephalexin | Cephalexin | 22 | 17 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Victoza 2-Pak | Liraglutide | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.58 · 10 records | ABBVIE INC. | Cologuard Collection Kit, Korlym, MINIMED 780G, MOUNJARO, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error